IndieBio

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

heXem bio specializes in recording solutions for the early development of humans for longevity.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Avisa Myko is a biotechnology company based in San Francisco, California. It specializes in the production of melanin, a natural pigment with applications in cosmetics, biomedicine, organic semiconductors, biosensors, and latex products. The company's patented technology enables large-scale production of soluble, affordable melanin, offering protection against ionizing radiation and contributing to better health and environmental sustainability.

Chronus Health develops a portable diagnostic device for delivering point-of-care lab results in minutes. Its device enables real-time diagnosis at the point-of-care, improving time to care and patient outcomes.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Hypercell Technologies develops tools to control infectious diseases in animals, including diagnostics and monoclonal antibodies designed to curb viruses in production animal reservoirs. The company employs molecular biology to create rapid, on-farm diagnostics that enable veterinarians to detect infections quickly and implement preventive measures. By focusing on proactive control of viruses in animal populations, Hypercell aims to reduce the emergence of diseases that could threaten human health and improve animal health management across production settings.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Avisa Myko is a biotechnology company based in San Francisco, California. It specializes in the production of melanin, a natural pigment with applications in cosmetics, biomedicine, organic semiconductors, biosensors, and latex products. The company's patented technology enables large-scale production of soluble, affordable melanin, offering protection against ionizing radiation and contributing to better health and environmental sustainability.

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles engineered to signal through validated targets. Diadem's therapeutic platform aims to treat a variety of chronic inflammatory conditions, autoimmune diseases, and cancers. By focusing on the genetic engineering, manufacturing, and purification of these exosomes, Diadem provides innovative solutions for clinicians to effectively address immunopathologies and improve patient outcomes.

Care Constitution operates a telehealth platform that facilitates remote medical consultations. It uses AI to analyze sound and images during virtual appointments, generating real-time clinical data and automated assessments for healthcare providers.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

BiomeSense develops an integrated hardware, software, and data platform to scale microbiome data collection and analysis for clinical research. The company integrates at-home monitoring of the gut microbiome through its GutLab smart-bathroom system with the MetaBiome time-series analytics platform to connect microbiome changes with clinical outcomes in real time. Its platform supports large-scale, densely longitudinal datasets to discover, validate, and commercialize microbiome biomarkers, enabling clinicians to apply microbiome insights to improve human health. Founded in 2018 and based in Chicago, BiomeSense seeks to advance precision medicine by providing end-to-end microbiome measurement and analytics.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Free to Feed is a company focused on enhancing breastfeeding experiences by providing solutions for detecting food allergens in breast milk. It offers an innovative over-the-counter allergen test that empowers breastfeeding mothers to identify various food proteins in their milk, which is crucial for those concerned about potential infant food allergies or intolerances. The company’s patented testing kits, combined with a mobile application, allow mothers to document the presence of allergens, the timing of milk expression, and any symptoms their infants may exhibit. This comprehensive data collection aids medical professionals in diagnosing and managing food allergies effectively. With a growing recognition of the importance of early allergen introduction to mitigate future allergies, Free to Feed supports parents in navigating these complexities with tailored counseling and technology, ensuring they can confidently meet their breastfeeding goals while safeguarding their infants' health.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

AnimalBiome specializes in personalized pet nutrition, focusing on improving gut health for dogs and cats through microbiome science. The company offers microbiome tests to analyze pets' gut bacteria and provides tailored restorative supplements sourced from healthy animals to balance the microbiome.

Founded in 2019, Kalia Health is a biotechnology company based in Chapel Hill, North Carolina. It develops affordable and accessible home-based early detection tests to improve maternal health outcomes.

Tesarakt is a New York City-based company founded in 2022 that specializes in developing predictive artificial intelligence technology for brain care. The company focuses on enhancing neuro-diagnosis by employing advanced artificial intelligence and machine learning techniques. Tesarakt utilizes a comprehensive database of conventional MRI scans to improve the predictive capabilities of medical professionals, enabling earlier detection of neurological disorders such as Parkinson's disease and Alzheimer's disease, often before the onset of initial symptoms. Through its innovative approach, Tesarakt aims to transform the way neurological conditions are diagnosed and managed.

Tesarakt is a New York City-based company founded in 2022 that specializes in developing predictive artificial intelligence technology for brain care. The company focuses on enhancing neuro-diagnosis by employing advanced artificial intelligence and machine learning techniques. Tesarakt utilizes a comprehensive database of conventional MRI scans to improve the predictive capabilities of medical professionals, enabling earlier detection of neurological disorders such as Parkinson's disease and Alzheimer's disease, often before the onset of initial symptoms. Through its innovative approach, Tesarakt aims to transform the way neurological conditions are diagnosed and managed.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Founded in 2019, Kalia Health is a biotechnology company based in Chapel Hill, North Carolina. It develops affordable and accessible home-based early detection tests to improve maternal health outcomes.

Avisa Myko is a biotechnology company based in San Francisco, California. It specializes in the production of melanin, a natural pigment with applications in cosmetics, biomedicine, organic semiconductors, biosensors, and latex products. The company's patented technology enables large-scale production of soluble, affordable melanin, offering protection against ionizing radiation and contributing to better health and environmental sustainability.

ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.

ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Cellens is a medical device company based in Medford, Massachusetts, and is a spinoff from Tufts University, established in 2019. The company focuses on enhancing cancer detection through noninvasive screening methods. It has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning to assist oncologists in the detection of bladder cancer. By analyzing physio-biomarkers on cell surfaces derived from urine samples, Cellens provides a diagnostic score that helps healthcare professionals minimize the need for invasive and costly procedures, thereby improving patient outcomes in bladder cancer diagnostics.

Cellens is a medical device company based in Medford, Massachusetts, and is a spinoff from Tufts University, established in 2019. The company focuses on enhancing cancer detection through noninvasive screening methods. It has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning to assist oncologists in the detection of bladder cancer. By analyzing physio-biomarkers on cell surfaces derived from urine samples, Cellens provides a diagnostic score that helps healthcare professionals minimize the need for invasive and costly procedures, thereby improving patient outcomes in bladder cancer diagnostics.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles engineered to signal through validated targets. Diadem's therapeutic platform aims to treat a variety of chronic inflammatory conditions, autoimmune diseases, and cancers. By focusing on the genetic engineering, manufacturing, and purification of these exosomes, Diadem provides innovative solutions for clinicians to effectively address immunopathologies and improve patient outcomes.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Chronus Health develops a portable diagnostic device for delivering point-of-care lab results in minutes. Its device enables real-time diagnosis at the point-of-care, improving time to care and patient outcomes.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Free to Feed is a company focused on enhancing breastfeeding experiences by providing solutions for detecting food allergens in breast milk. It offers an innovative over-the-counter allergen test that empowers breastfeeding mothers to identify various food proteins in their milk, which is crucial for those concerned about potential infant food allergies or intolerances. The company’s patented testing kits, combined with a mobile application, allow mothers to document the presence of allergens, the timing of milk expression, and any symptoms their infants may exhibit. This comprehensive data collection aids medical professionals in diagnosing and managing food allergies effectively. With a growing recognition of the importance of early allergen introduction to mitigate future allergies, Free to Feed supports parents in navigating these complexities with tailored counseling and technology, ensuring they can confidently meet their breastfeeding goals while safeguarding their infants' health.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Microgenesis is a biotechnology company focused on fertility and pregnancy health monitoring. It has developed a platform that provides a non-invasive fertility test and personalized nutritional supplementation aimed at restoring women's fertility potential. The company's innovative diagnostic approach detects subclinical inflammation that negatively impacts ovarian function and implantation, specifically targeting women who have experienced challenges, including multiple failed IVF attempts. Operating out of a CLIA lab in Oakland, Microgenesis offers its solutions through OB-GYNs and direct-to-consumer channels. Additionally, the platform addresses imbalances in vaginal and intestinal microbiota linked to infertility and offers dual testing for immunological issues related to the endometrium, equipping patients with effective treatment options for complex reproductive health cases.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

EMBER Medical is a telehealth company based in San Francisco, California, founded in 2018. It develops a mobile application that connects individuals experiencing medical emergencies with nearby healthcare professionals, including physicians, nurses, and emergency medical technicians, within a five-minute radius. The application features in-app audio and video capabilities, allowing users to communicate directly with medical staff for immediate assistance. EMBER Medical aims to enhance the accessibility of healthcare, particularly in underserved areas, by providing a platform that enables patients to receive timely and personalized care without the need for in-person visits. The company's technology also offers healthcare providers various tools to manage virtual consultations effectively.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

BiomeSense develops an integrated hardware, software, and data platform to scale microbiome data collection and analysis for clinical research. The company integrates at-home monitoring of the gut microbiome through its GutLab smart-bathroom system with the MetaBiome time-series analytics platform to connect microbiome changes with clinical outcomes in real time. Its platform supports large-scale, densely longitudinal datasets to discover, validate, and commercialize microbiome biomarkers, enabling clinicians to apply microbiome insights to improve human health. Founded in 2018 and based in Chicago, BiomeSense seeks to advance precision medicine by providing end-to-end microbiome measurement and analytics.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Founded in 2020, Advanced Microbubbles specializes in developing microbubble technology for targeted drug delivery. Utilizing ultrasound, the company's products temporarily open barriers like the blood-brain barrier to facilitate local drug entry, enhancing precision and reducing side effects.

Founded in 2020, Advanced Microbubbles specializes in developing microbubble technology for targeted drug delivery. Utilizing ultrasound, the company's products temporarily open barriers like the blood-brain barrier to facilitate local drug entry, enhancing precision and reducing side effects.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Convalesce Inc. is a San Francisco-based company that focuses on developing stem cell-based therapies for neurological disorders characterized by neuronal degeneration, such as Parkinson's disease. Founded in 2018, Convalesce specializes in creating implantable biomaterials designed to enhance stem cell therapy effectiveness. These innovative biomaterials address critical challenges related to the survival and differentiation of stem cells into neurons after implantation. By leveraging advanced biomaterials, the company aims to enable medical professionals to regenerate lost neuronal networks in patients suffering from neurodegenerative conditions, ultimately improving treatment outcomes.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.